| Title: | SARS-CoV-2 infection in alpha1-antitrypsin deficiency |
| Journal: | Respiratory Medicine |
| Published: | 13 May 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34010739/ |
| DOI: | https://doi.org/10.1016/j.rmed.2021.106466 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116136 |
| Citations: | 12 (5 in last 2 years) as of 8 Aug 2024 |
Publication 7288
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Alpha1-antitrypsin deficiency arises due to mutations in alpha1-antitrypsin (AAT) gene and represents the most prominent genetic predisposition to chronic obstructive pulmonary disease and emphysema. Since AAT plays important immunomodulatory and tissue-protective roles and since it was suggested to protect from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we assessed this association in United Kingdom Biobank, a community-based cohort with >500,000 participants. The most common, mild AATD genotypes were associated neither with increased SARS-CoV-2 infection rates nor with increased SARS-CoV-2 fatalities, while the numbers of severe AATD cases were too low to allow definitive conclusions.2 Authors
- Carolin V Schneider
- Pavel Strnad
1 Application
| Application ID | Title |
|---|---|
| 47527 | Analysis of Alpha1-Antitrypsin related comorbidities |
Enabling scientific discoveries that improve human health